oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 New in the September 18, 2025, issue of NEJM: Aspirin for PI3K-Altered Localized Colorectal Cancer (ALASCCA phase 3 trial) https://nej.md/4mpKXNp Orforglipron in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) https://nej.md/4ngEZ36 oasis 1 trial oral semaglutide

L-carnitine fumarate, N-acetyl-L-carnitine, magnesium citrate, coating agents: Hydroxypropylmethylcellulose, coenzyme Q10, camu camu extract Food supplement: Do not exceed the recommended daily intake stated

If the patient meets FDA labeling criteria for a GLP-1 agent (BMI 30, or BMI 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), the clinician issues a prescription

To build habits that last Medication can support fat loss, but long-term success still comes down to routine, structure and habits

They are chemical compounds with an indirect link between an aromatic molecule and a hydroxyl group

Muscle tissue burns calories at rest and supports metabolism

doi: 10.3389/fnut.2024.1393673 Received 29 February 2024 Accepted 29 May 2024 Published 12 June 2024 Volume 11 - 2024 Edited by Franziska Roth-Walter, University of Veterinary Medicine Vienna, Austria Reviewed by Jennifer L